TI
BOLD

Trexquant Investment’s Audentes Therapeutics, Inc BOLD Stock Holding History

Trexquant Investment’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-42,197
Closed -$900K – 1457
2018
Q4 		$900K Buy
+42,197
New +$1.09M 0.06% 448
2018
Q2 		– Sell
-20,305
Closed -$610K – 1388
2018
Q1 		$610K Buy
20,305
+11,080
+120% +$375K 0.04% 574
2017
Q4 		$288K Sell
9,225
-1,311
-12% -$36K 0.03% 770
2017
Q3 		$295K Buy
+10,536
New +$229K 0.07% 472

Other funds holding BOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Trexquant Investment's BOLD Position: Q1 2019 in Review

Trexquant Investment sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2019, closing a stake of 42,197 shares — an estimated $900K sold.

Trexquant Investment first reported a position in BOLD in Q3 2017 and held it in 4 quarters. The position peaked at $900K in Q4 2018. 139 funds tracked by Wall St. Rank hold BOLD as of Q1 2019.

  • Trexquant Investment reported no remaining Audentes Therapeutics, Inc position as of Q1 2019 after selling out during the quarter.
  • Trexquant Investment sold 42,197 Audentes Therapeutics, Inc shares in Q1 2019, an estimated $900K.
  • Trexquant Investment first reported a position in Audentes Therapeutics, Inc in Q3 2017 and held it in 4 quarters.
  • Trexquant Investment's Audentes Therapeutics, Inc position peaked at $900K in Q4 2018.
  • 139 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2019.

Based on Trexquant Investment's 13F filing for Q1 2019, filed 13 May 2019.